Evoke PharmaEVOK
13F holders, Q4 2024 (December 31)8holders −4
0new positions
5sold out
$4.42avg. 13F price*
At the end of Q4 2024, 8 institutions reported holding Evoke Pharma Inc. (EVOK) in their 13F filings, down 4 from Q3 2024. 0 opened new positions and 5 sold out. The largest holders were Nantahala Capital Management, LLC ($655K), Bleichroeder LP ($304K) and UBS Group AG ($6K).
- Company
- Evoke Pharma Inc.
- CUSIP
- 30049G302
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 5 | $398K |
All 13F filers, Q3 2024 → Q4 2024: 93,113 shares bought and 83,051 shares sold, net +10,062 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| Nantahala Capital Management, LLC | 0.05% | Add +163.5% | 148,194 | $655K |
| Bleichroeder LP | 0.08% | No change | 68,750 | $304K |
| UBS Group AG | 0.00% | Add +1297.8% | 1,258 | $6K |
| BlackRock, Inc. | 0.00% | No change | 122 | $539 |
| SBI Securities Co., Ltd. | 0.00% | — | 75 | $332 |
| Morgan Stanley | 0.00% | No change | 31 | $137 |
| NewEdge Advisors, LLC | 0.00% | No change | 17 | $75 |
| Bank of America Corp. | 0.00% | Reduce -64.0% | 9 | $40 |
"% of holder's portfolio" is EVOK's weight in each manager's 13F, not the share of Evoke Pharma Inc. the manager owns.